BIOMAT Database Logo BIOMAT Database Logo

Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. 1994

J C Fleishaker, and L K Hulst, and G R Peters
Clinical Pharmacokinetics Unit, Upjohn Company, Kalamazoo, MI 49007.

The potential interaction between tirilazad mesylate, a membrane lipid peroxidation inhibitor, and nimodipine, a calcium-channel antagonist, was assessed in 12 healthy male volunteers. Subjects received 60 mg nimodipine orally, 2.0 mg/kg tirilazad mesylate as a 10-minute intravenous infusion, and a combination of the two treatments according to a balanced 3-way crossover design. No significant effects of nimodipine on tirilazad mesylate pharmacokinetic parameters were observed (P > .05). Values for tirilazad mesylate clearance (34.9 +/- 8.96 L/hr) and half-life (29 +/- 7.83 hr) were consistent with previous studies. Nimodipine pharmacokinetic parameters exhibited substantial variability, and mean AUC was approximately 25% below the range of previously published values. However, no significant differences in nimodipine pharmacokinetics were observed between treatments. Nimodipine administration increased heart rate slightly without a change in blood pressure, which was not observed after tirilazad administration and was not altered when tirilazad and nimodipine were coadministered. Thus, no significant interaction between tirilazad mesylate and nimodipine is detectable after single-dose administration.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D009553 Nimodipine A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. Admon,Bay e 9736,Brainal,Calnit,Kenesil,Modus,Nimodipin Hexal,Nimodipin-ISIS,Nimodipino Bayvit,Nimotop,Nymalize,Remontal,Bayvit, Nimodipino,Hexal, Nimodipin,Nimodipin ISIS,e 9736, Bay
D011281 Pregnatrienes Pregnane derivatives containing three double bonds in the ring structures.
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J C Fleishaker, and L K Hulst, and G R Peters
Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers.
May 2006, Pharmacotherapy,
J C Fleishaker, and L K Hulst, and G R Peters
Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.
January 2006, Antimicrobial agents and chemotherapy,
J C Fleishaker, and L K Hulst, and G R Peters
The pharmacokinetic and pharmacodynamic interaction between lacidipine and propranolol in healthy volunteers.
January 1991, Journal of cardiovascular pharmacology,
J C Fleishaker, and L K Hulst, and G R Peters
Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers.
January 1994, European journal of clinical pharmacology,
J C Fleishaker, and L K Hulst, and G R Peters
Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
May 2018, European journal of clinical pharmacology,
J C Fleishaker, and L K Hulst, and G R Peters
Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers.
January 1999, Chemotherapy,
J C Fleishaker, and L K Hulst, and G R Peters
Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers.
March 2000, Journal of clinical pharmacology,
J C Fleishaker, and L K Hulst, and G R Peters
Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers.
May 2013, Journal of cardiovascular pharmacology,
J C Fleishaker, and L K Hulst, and G R Peters
Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
July 2010, Journal of clinical pharmacology,
J C Fleishaker, and L K Hulst, and G R Peters
Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers.
October 2018, Clinical therapeutics,
Copied contents to your clipboard!